ESC 2020 | More Evidence on Colchicine for Chronic Ischemic Heart Disease

According to this new study, colchicine offers some benefit to patients with chronic ischemic heart disease. Similar to COLCOT, this is the second large randomized study with results confirming the inflammatory hypothesis.

ESC 2020 | La colchicina suma evidencia en cardiopatía isquémica crónica

Colchicine taken at a daily dose of 0.5 mg reduces cardiovascular events in patients with stable coronary disease, according to data from the LoDoCo2 trial, presented at the 2020 European Society of Cardiology (ESC) virtual congress and published simultaneously in the New England Journal of Medicine (NEJM).

LoDoCo2 provides strong evidence to support the inclusion of colchicine in the routine secondary prevention toolbox for patients with chronic ischemic heart disease.

This study included 5522 patients with coronary artery disease (any evidence of it, including a coronary artery calcium score of >400 Agatston units) clinically stable for the last 6 months, who were randomized to cholchicine 0.5 mg or placebo.

Mean age was 66 years, and only 15.3% of patients were female. While 84.4% of patients had a history of acute coronary syndrome, in most cases, their event had happened more than 2 years before the randomization.


Read also: AHA 2019 | COLCOT: Colchicine and the Return of the Anti-Inflammatory Theory.


Optimal medical treatment recommended by the guidelines had high adherence.

After a mean follow-up duration of 28.6 months, 6.8% of patients in the colchicine group experienced a cardiovascular event (cardiovascular death, infarction, stroke, ischemia-driven revascularization) compared with 9.6% of patients in the placebo group (hazard ratio [HR]: 0.69; 95% confidence interval [CI]: 0.57-0.83). These figures are significant and were consistent across all subgroups.

Ischemia-driven revascularization and infarctions considered individually also were significantly less frequent in the colchicine group.


Read also: Post-MI Colchicine: Cost-Effective with Good Results


Colchicine plus optimal medical treatment reduces by around 30% the risk of future events.

Lodoco2-full

Original Title: Colchicine in patients with chronic coronary disease.

Reference: Nidorf SM et al. N Engl J Med. 2020; Epub ahead of print y presentado en el congreso ESC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...